GlassScriptPhysician profile
Ginger M Atkinson
NPI 1982945762
$13,924.76
in general payments reported to CMS, 2019-2025
33 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $3,291 · 2023: $3,542 · 2024: $3,563 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,292 · Education: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,291.94 |
| Education | $515.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,586.80 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,733.69 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $1,580.53 | 2021-2025 | |
| Janssen Biotech, INC. | $893.05 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $852.25 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $811.84 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $667.41 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $656.79 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $594.51 | 2021-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $553.11 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $428.98 | 2021-2025 | |
| Incyte Corporation | $418.92 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $370.13 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Novartis Pharmaceuticals Corporation | $355.06 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $279.26 | 2021-2025 | Arazlo, Cabtreo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $172.08 | 2022-2024 | Klisyri |
| Arcutis Biotherapeutics, INC. | $143.04 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $135.30 | 2023-2024 | Vtama |
| Genentech USA, INC. | $94.09 | 2022-2024 | Xolair |
| Organogenesis INC. | $77.09 | 2024-2025 | Apligraf |
| Biofrontera INC. | $76.73 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Epi Health, LLC | $51.53 | 2022 | |
| Convatec INC. | $48.81 | 2023 | |
| Mayne Pharma Commercial LLC | $48.64 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.49 | 2023 | Spevigo |
| Botanix Sb INC | $48.17 | 2025 | Sofdra |
| Journey Medical Corporation | $48.01 | 2022-2024 | |
| Lnhc, INC | $44.82 | 2025 | Zelsuvmi |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Sandoz INC. | $24.38 | 2024 | Hyrimoz |
| Organon LLC | $20.79 | 2025 | |
| Smith+Nephew, INC. | $17.11 | 2023 | Stravix, Grafix, Grafix Pl |
| Strata Skin Sciences, INC. | $16.85 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.